Literature DB >> 16624282

Inhibitory mechanisms of activated matrix metalloproteinase-9 on platelet activation.

Ye-Ming Lee1, Jie-Jen Lee, Ming-Yi Shen, George Hsiao, Joen-Rong Sheu.   

Abstract

The intracellular mechanisms underlying the signaling pathways of activated matrix metalloproteinase-9 (MMP-9) in platelets are not yet completely understood. Therefore, the aim of this study was to further examine the effects of activated MMP-9 in preventing platelet aggregation. In this study, activated MMP-9 time-dependently (3-60 min) inhibited platelet aggregation in washed human platelet suspensions stimulated by agonists. However, activated MMP-9 had no significant effect on the binding of FITC-triflavin to the platelet glycoprotein IIb/IIIa complex. Triflavin is a specific antagonist of the glycoprotein IIb/IIIa complex purified from snake venom. Moreover, activated MMP-9 (21 and 90 ng/ml) markedly decreased the fluorescence intensity of platelet membranes tagged with diphenylhexatriene. The thrombin-evoked increase in pHi was inhibited in the presence of activated MMP-9 (21 and 90 ng/ml). In addition, activated MMP-9 (21 and 90 ng/ml) markedly reduced the electron spin resonance (ESR) signal intensity of hydroxyl radicals in collagen (1 mug/ml)-activated platelets. These results indicate that the antiplatelet activity of activated MMP-9 may involve the following pathways: (1) activated MMP-9 may initially induce conformational changes in platelet membranes and hydroxyl radical formation, leading to inhibition of platelet aggregation; and (2) activated MMP-9 also inhibits the Na(+)/H(+) exchanger, leading to reduced intracellular Ca(2+) mobilization, and ultimately to inhibition of platelet aggregation. This study further provides new insights concerning the effects of activated MMP-9 on platelet aggregation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16624282     DOI: 10.1016/j.ejphar.2006.03.031

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Identification of key pathogenic genes of sepsis based on the Gene Expression Omnibus database.

Authors:  Xinxing Lu; Lu Xue; Wenbin Sun; Jilu Ye; Zhiyun Zhu; Haifeng Mei
Journal:  Mol Med Rep       Date:  2017-12-12       Impact factor: 2.952

2.  Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.

Authors:  Leonardo Lorente; María M Martín; Lorenzo Labarta; César Díaz; Jordi Solé-Violán; José Blanquer; Josune Orbe; José A Rodríguez; Alejandro Jiménez; Juan M Borreguero-León; Felipe Belmonte; Juan C Medina; Maria C Llimiñana; José M Ferrer-Agüero; José Ferreres; María L Mora; Santiago Lubillo; Manuel Sánchez; Ysamar Barrios; Antonio Sierra; José A Páramo
Journal:  Crit Care       Date:  2009-10-02       Impact factor: 9.097

3.  The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis.

Authors:  Leonardo Lorente; Mar Martín; Fátima Plasencia; Jordi Solé-Violán; José Blanquer; Lorenzo Labarta; César Díaz; Juan María Borreguero-León; Alejandro Jiménez; José Antonio Páramo; Josune Orbe; José A Rodríguez; Eduardo Salido
Journal:  Crit Care       Date:  2013-05-25       Impact factor: 9.097

4.  Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio.

Authors:  Leonardo Lorente; María M Martín; Jordi Solé-Violán; José Blanquer; Lorenzo Labarta; César Díaz; Juan M Borreguero-León; Josune Orbe; José A Rodríguez; Alejandro Jiménez; José A Páramo
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.